Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOJL61)

Drug Name
GNF-PF-3955 Drug Info
Synonyms
GNF-Pf-3955; MLS000073091; SMR000013108; 500276-85-7; 2-Imino-8-methyl-10-oxo-1-phenethyl-1,10-dihydro-2H-1,9,10a-triaza-anthracene-3-carboxylic acid (furan-2-ylmethyl)-amide; BAS 04995279; regid844814; AC1LDF87; MLS001385288; CHEMBL605747; cid_647145; BDBM49996; MolPort-000-197-560; HMS2774A18; STK703431; ZINC100662448; AKOS001655389; MCULE-3107531902; EU-0080883; Z57780857; N-(furan-2-ylmethyl)-2-imino-10-methyl-5-oxo-1-(2-phenylethyl)dipyrido[3,4-c:1'',2''-f]pyrimidine-3-carboxamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
647145
TTD Drug ID
DMOJL61

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
AZD5991 DM7QGHO Haematological malignancy 2B33.Y Phase 1 [3]
AMG 176 DM0Q7NO Acute myeloid leukaemia 2A60 Phase 1 [3]
PRT1419 DMIKE0O Melanoma 2C30 Phase 1 [4]
ABBV-467 DM87SM9 Multiple myeloma 2A83 Phase 1 [5]
MIK665 DMTUVCG Acute myeloid leukaemia 2A60 Phase 1 [6]
AMG 397 DM7CNTG Refractory hematologic malignancy 2A85.5 Phase 1 [7]
PMID27744724-Compound-18 DM73S2C N. A. N. A. Patented [8]
Indole-based analog 2 DM0NEVC N. A. N. A. Patented [8]
PMID27744724-Compound-10 DMFKS2P N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) TTL53M6 MCL1_HUMAN Inhibitor [1]

References

1 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
2 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Prelude Therapeutics.
5 Clinical pipeline report, company report or official report of AbbVie.
6 MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
7 Clinical pipeline report, company report or official report of Amgen.
8 Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.